AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18450829 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 885
Study 18450829 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 885
Study 16642224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling the blood and invigorating blood circulation decoction
Number of subjects: 72
Study 16642224 — intervention group
Group type: COMPARATOR
Intervention: Hepatocyte growth factor (HGF) 80-120 mg daily
Number of subjects: 72
Study 12560956 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (40 maximal eccentric contractions of the anterior tibial muscles at an angular velocity of 90 degrees s‐1)
Number of subjects: 10
Study 12560956 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 10
Study 10881805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (300-mg bolus and 20 mg x kg(‐1) x day(‐1) for 3 days)
Number of subjects: 150
Study 10881805 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (150-mg bolus and 10 mg x kg(‐1) x day(‐1) for 3 days)
Number of subjects: 150
Study 10881805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 9179578 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponing Sexual Involvement (PSI) curriculum implemented by adult or youth leaders
Number of subjects: 10600
Study 9179578 — intervention group
Group type: EXPERIMENTAL
Intervention: Postponing Sexual Involvement (PSI) curriculum
Number of subjects: 10600
Study 7504824 — intervention group
Group type: EXPERIMENTAL
Intervention: Brofaromine
Number of subjects: 0
Study 7504824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3517075 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine (CH)
Number of subjects: 22
Study 3517075 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% metronidazole (MD)
Number of subjects: 22
Study 3517075 — intervention group
Group type: COMPARATOR
Intervention: Inactive control (PL)
Number of subjects: 22
Study 31470737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF) measured by maximal cardiorespiratory stress test and peak oxygen uptake
Number of subjects: 109
Study 31470737 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 109
Study 29921245 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary and hygiene behaviour intervention
Number of subjects: 0
Study 26732827 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6ng/kg LPS
Number of subjects: 52
Study 26732827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 25212080 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted, trivalent, influenza vaccine (ATIV)
Number of subjects: 360
Study 25212080 — intervention group
Group type: COMPARATOR
Intervention: Non‐adjuvanted, trivalent, influenza vaccine (TIV)
Number of subjects: 360
Study 23188899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented all‐polyethylene Ultima acetabular component (Group A)
Number of subjects: 287
Study 23188899 — intervention group
Group type: COMPARATOR
Intervention: Cementless porous‐coated acetabular component (Group B)
Number of subjects: 287
Study 20172072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg)
Number of subjects: 32
Study 20172072 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (1.25 mg)
Number of subjects: 32
Study 18793546 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin-beta 6,000 IU (0.3 ml)
Number of subjects: 40
Study 18793546 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin-alpha 30 mg (0.3 ml)
Number of subjects: 40
Study 18793546 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16055640 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive and negative religious (Christian) symbols presented outside of conscious awareness
Number of subjects: 0
Study 16055640 — intervention group
Group type: COMPARATOR
Intervention: Similar images lacking Christian meaning
Number of subjects: 0
Study 12150618 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide (256 microg daily)
Number of subjects: 26
Study 12150618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12150618 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide
Number of subjects: 26
Study 10541947 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapy (24 hours exposure, wavelength 425-475 nm)
Number of subjects: 50
Study 10541947 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated neonates)
Number of subjects: 50
Study 7599840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm NO during ZEEP
Number of subjects: 21
Study 7599840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm NO during PEEP
Number of subjects: 21
Study 7599840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm NO during ZEEP (no alveolar recruitment)
Number of subjects: 21
Study 7599840 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm NO during PEEP (no alveolar recruitment)
Number of subjects: 21
Study 7599840 — intervention group
Group type: COMPARATOR
Intervention: ZEEP
Number of subjects: 21
Study 7599840 — intervention group
Group type: COMPARATOR
Intervention: 10 cm H2O PEEP
Number of subjects: 21
Study 2089822 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 11
Study 2089822 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% placebo
Number of subjects: 11
Study 340492 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzable transfer factor (TF)
Number of subjects: 33
Study 340492 — intervention group
Group type: EXPERIMENTAL
Intervention: Column purified transfer factor (TF)
Number of subjects: 33
Study 340492 — intervention group
Group type: COMPARATOR
Intervention: Hypoxanthine
Number of subjects: 33
Study 340492 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 33
Study 31566307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily
Number of subjects: 663
Study 31566307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 663
Study 31566307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg twice daily (UIP-like fibrotic pattern)
Number of subjects: 663
Study 31566307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (UIP-like fibrotic pattern)
Number of subjects: 663
Study 31566307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 663
Study 29089019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) at a minimum recommended dose rate of 20 mg/kg
Number of subjects: 0
Study 29089019 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™)
Number of subjects: 0
Study 29089019 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study 26355167 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mm-long implants
Number of subjects: 150
Study 26355167 — intervention group
Group type: COMPARATOR
Intervention: 8.5 mm-long implants
Number of subjects: 150
Study 23801734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar cortex excitation
Number of subjects: 0
Study 23801734 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar cortex inhibition
Number of subjects: 0
Study 23801734 — intervention group
Group type: COMPARATOR
Intervention: Cerebellar cortex excitation and inhibition
Number of subjects: 0
Study 23801734 — intervention group
Group type: COMPARATOR
Intervention: Behavioral parameters reflecting adaptation capacity
Number of subjects: 0
Study 21368429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabdosia rubescens aqueous extract, 220 mL once a day for 30 days
Number of subjects: 102
Study 21368429 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 220 mL once a day for 30 days
Number of subjects: 102
Study 21368429 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabdosia rubescens aqueous extract
Number of subjects: 102
Study 21368429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 19142085 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐rich drink (400 ml) at 6‐7 a.m.
Number of subjects: 210
Study 19142085 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight intravenous 5% glucose infusion (1000 ml)
Number of subjects: 210
Study 19142085 — intervention group
Group type: COMPARATOR
Intervention: Overnight fasting
Number of subjects: 210
Study 18087557 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSC (bone marrow mononuclear stem cells) group
Number of subjects: 42
Study 15494915 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of coenzyme Q twice daily for 3 months
Number of subjects: 35
Study 15494915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11215725 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0
Study 11215725 — intervention group
Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 0
Study 9391289 — intervention group
Group type: EXPERIMENTAL
Intervention: QTPEAK dispersion tertile (> or = 50 ms)
Number of subjects: 72
Study 9391289 — intervention group
Group type: EXPERIMENTAL
Intervention: QTPEAK dispersion tertile (> or = 50 ms) after adjustment for left ventricular hypertrophy
Number of subjects: 72
Study 9391289 — intervention group
Group type: EXPERIMENTAL
Intervention: QTEND dispersion in pre-event ECGs
Number of subjects: 72
Study 9391289 — intervention group
Group type: COMPARATOR
Intervention: QT dispersion in baseline ECG
Number of subjects: 72
Study 8350435 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Saver Autotransfusion Device (n = 18)
Number of subjects: 96
Study 8350435 — intervention group
Group type: COMPARATOR
Intervention: No Cell Saver Autotransfusion Device (n = 18)
Number of subjects: 96
Study 3737440 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 0
Study 3737440 — intervention group
Group type: COMPARATOR
Intervention: Codeine phosphate 60 mg
Number of subjects: 0
Study 3737440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of acetaminophen 1000 mg and codeine phosphate 60 mg
Number of subjects: 0
Study 31651355 — intervention group
Group type: EXPERIMENTAL
Intervention: Sahaj Samadhi meditation (SSM)
Number of subjects: 192
Study 31651355 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 192
Study 29154277 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg twice a day
Number of subjects: 800
Study 29154277 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg twice a day (monotherapy)
Number of subjects: 800
Study 29154277 — intervention group
Group type: COMPARATOR
Intervention: 4 mg twice a day (add-on therapy)
Number of subjects: 800
Study 27181733 — intervention group
Group type: EXPERIMENTAL
Intervention: $AFE (Money Management Intervention)
Number of subjects: 144
Study 27181733 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 144
Study 24457999 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-alanine (6.4 g/day for 6 weeks)
Number of subjects: 27
Study 24457999 — intervention group
Group type: COMPARATOR
Intervention: placebo (6.4 g/day for 6 weeks)
Number of subjects: 27
Study 23183517 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (eicosapentaenoic and docosahexaenoic acid ethyl esters, 3.0 g/d)
Number of subjects: 60
Study 20647406 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient support and navigation intervention (one call from a professional health worker and multiple calls from a lay health worker)
Number of subjects: 1708
Study 20647406 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1708
Study 17445403 — intervention group
Group type: EXPERIMENTAL
Intervention: Transballoon ultrasound ablation catheter during mitral valve replacement surgery
Number of subjects: 21
Study 15823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous intervention for physical activity and fat intake
Number of subjects: 771
Study 15823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intervention for physical activity followed by fat intake
Number of subjects: 771
Study 15823787 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential intervention for fat intake followed by physical activity
Number of subjects: 771
Study 15823787 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 771
Study 11994339 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (30 mg/d if <45 yr of age and 20 mg if >=45 yr of age) for 6 months
Number of subjects: 38
Study 11994339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 9920063 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (125 microg/kg)
Number of subjects: 60
Study 9920063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 60
Study 7802305 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with sufentanil and concomitant infusion of sufentanil
Number of subjects: 40
Study 7802305 — intervention group
Group type: COMPARATOR
Intervention: PCEA with sufentanil and concomitant infusion of saline (control)
Number of subjects: 40
Study 2334617 — intervention group
Group type: EXPERIMENTAL
Intervention: Local analgesia (retrobulbar block)
Number of subjects: 18
Study 2334617 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 18
Study 380630 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple intradermal injections of absolute alcohol
Number of subjects: 17
Study 380630 — intervention group
Group type: COMPARATOR
Intervention: Water injections (control)
Number of subjects: 17
Study 31812227 — intervention group
Group type: EXPERIMENTAL
Intervention: COL1A1 (collagen α‐1(I) chain)
Number of subjects: 1007
Study 31812227 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP‐6 (bone morphogenetic protein‐6)
Number of subjects: 1007
Study 31812227 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐6Rα (interleukin‐6 receptor α chain)
Number of subjects: 1007
Study 31812227 — intervention group
Group type: COMPARATOR
Intervention: Low COL1A1, low BMP‐6, and high IL‐6Rα levels
Number of subjects: 1007
Study 31778193 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal hygiene strategies for SSTI prevention
Number of subjects: 0
Study 31778193 — intervention group
Group type: EXPERIMENTAL
Intervention: S. aureus vaccine trial (Phase 2)
Number of subjects: 0
Study 27964769 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational review session
Number of subjects: 292
Study 27964769 — intervention group
Group type: EXPERIMENTAL
Intervention: Aide-memoir
Number of subjects: 292
Study 27964769 — intervention group
Group type: EXPERIMENTAL
Intervention: Both educational review and aide-memoir
Number of subjects: 292
Study 27964769 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 292
Study 26027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 945
Study 26027431 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 945
Study 26027431 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 945
Study 24140184 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib titration (5 mg twice daily during a 4 week lead-in, then titrated to 7 mg and 10 mg if tolerated)
Number of subjects: 213
Study 24140184 — intervention group
Group type: COMPARATOR
Intervention: Placebo titration
Number of subjects: 213
Study 24140184 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised group (no titration)
Number of subjects: 213
Study 24140184 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib titration
Number of subjects: 213
Study 24140184 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised group
Number of subjects: 213
Study 21902287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine combined with naltrexone
Number of subjects: 0
Study 21902287 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine alone
Number of subjects: 0
Study 19696703 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step sclerotomy
Number of subjects: 12
Study 19696703 — intervention group
Group type: COMPARATOR
Intervention: Two-step sclerotomy
Number of subjects: 12
Study 17941363 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy moisturizer containing nondenaturated STI and BBI
Number of subjects: 65
Study 17941363 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 65
Study 15483463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily
Number of subjects: 0
Study 15483463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15483463 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF)
Number of subjects: 0
Study 11696966 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping-enhanced counseling
Number of subjects: 0
Study 11696966 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 0
Study 9817605 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol (Logimax®)
Number of subjects: 0
Study 9817605 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 8164053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg/d for 2 years
Number of subjects: 50
Study 8164053 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 6731771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-dissolving oral preparation of oxazepam, administered at least one hour pre-operatively
Number of subjects: 0
Study 31733783 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitland's postero‐anterior (PA glide) mobilization
Number of subjects: 33
Study 31733783 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's sustained natural apophyseal glide (SNAG)
Number of subjects: 33
Study 30196031 — intervention group
Group type: EXPERIMENTAL
Intervention: No axillary dissection
Number of subjects: 934
Study 30196031 — intervention group
Group type: COMPARATOR
Intervention: Axillary dissection
Number of subjects: 934
Study 27212429 — intervention group
Group type: COMPARATOR
Intervention: bOPV (3 doses)
Number of subjects: 939
Study 27212429 — intervention group
Group type: COMPARATOR
Intervention: tOPV (3 doses)
Number of subjects: 939
Study 27212429 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV + 1 dose IPV
Number of subjects: 939
Study 27212429 — intervention group
Group type: EXPERIMENTAL
Intervention: bOPV + 2 doses IPV
Number of subjects: 939
Study 27212429 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV (1 or 2 doses)
Number of subjects: 939
Study 24184649 — intervention group
Group type: EXPERIMENTAL
Intervention: TLSO (Thoracolumbosacral Orthosis)
Number of subjects: 96
Study 24184649 — intervention group
Group type: COMPARATOR
Intervention: No Orthosis (NO)
Number of subjects: 96
Study 22304891 — intervention group
Group type: EXPERIMENTAL
Intervention: Suffocation script condition (CS+) with inhalation of 35% CO(2) as UCS
Number of subjects: 33
Study 22304891 — intervention group
Group type: COMPARATOR
Intervention: Neutral script condition (CS-) with inhalation of room air
Number of subjects: 33
Study 22304891 — intervention group
Group type: COMPARATOR
Intervention: Urgency script condition (CS-) with inhalation of room air
Number of subjects: 33
Study 19357421 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention (n = 12)
Number of subjects: 22
Study 19357421 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 10)
Number of subjects: 22
Study 19357421 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 22
Study 17606546 — intervention group
Group type: EXPERIMENTAL
Intervention: New diaper‐changing, hand‐washing, and food‐preparation equipment
Number of subjects: 46
Study 17606546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no new equipment, but received hygiene training)
Number of subjects: 46
Study 18705977 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity implementation strategy for intravenous thrombolysis
Number of subjects: 12
Study 18705977 — intervention group
Group type: COMPARATOR
Intervention: Regular implementation strategy for intravenous thrombolysis
Number of subjects: 12
Study 15304146 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality circles intervention (11 sessions and repeated feedback on prescribing)
Number of subjects: 100000
Study 15304146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no quality circles intervention)
Number of subjects: 100000
Study 11068591 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation
Number of subjects: 0
Study 11068591 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 0
Study 8979328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autologous transfusion with hemodilution and apheresis
Number of subjects: 0
Study 8979328 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autologous transfusion alone
Number of subjects: 0
Study 8979328 — intervention group
Group type: COMPARATOR
Intervention: Conventional transfusion therapy (retrospective cohort)
Number of subjects: 0
Study 1334284 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 828
Study 1334284 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 828
Study 3880993 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 8
Study 31403325 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary probing only
Number of subjects: 102
Study 31403325 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary probing with monocanalicular silastic stent intubation
Number of subjects: 102
Study 31403325 — intervention group
Group type: COMPARATOR
Intervention: External dacryocystorhinostomy (for failure cases)
Number of subjects: 102
Study 30595357 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with new-generation drug-eluting stents (DES)
Number of subjects: 3986
Study 30595357 — intervention group
Group type: COMPARATOR
Intervention: CABG (historical DELTA-1 cohort)
Number of subjects: 3986